Nuvation Bio is trading at $5.66 (4.2% down) with investors continuing to react to its recently completed $287.5 million convertible senior notes offering. - The offering, which finalized on July 6, 2026, included the full exercise of a $37.5 million over-allotment option, sparking concerns over potential equity dilution. - Ongoing selling pressure and broader risk-off sentiment in the biotechnology sector are further weighing on the share price.